search for




 

Risk Factors Associated with Bisphosphonates Related Osteonecrosis of the Jaw: A National Insurance Senior Cohort Database Study
Yakhak Hoeji 2022;66(4):210-215
Published online August 31, 2022
© 2022 The Pharmaceutical Society of Korea.

Jun Hyeob Kim*, Tae Hyeok Kim*, and Kyung Eun Lee*,#

*College of Pharmay, Chungbuk National University
Correspondence to: Kyung Eun Lee, College of Pharmacy, Chungbuk National University, 660-1 Yeonje-ri, Osong-eup, Heungdeok-gu, Cheongju 28160, Republic of Korea
Tel: +82-43-261-3590, Fax: +82-43-268-2732
E-mail: kaylee@cbnu.ac.kr
Received July 16, 2022; Revised August 30, 2022; Accepted August 31, 2022.
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe side effect of bisphosphonate, which is usually prescribed as a treatment for diseases such as multiple myeloma, bone metastases, osteoporosis, and Paget disease. To investigate the risk factors of BRONJ, we conducted a nested case-control study using the Korean National Insurance Health Service-senior cohort. Patients newly diagnosed with BRONJ were selected as the case group, while the control group included patients who were never diagnosed with BRONJ. A risk-set sampling method was used to select the control group using age, sex, the date of the first prescription of bisphosphonate, and follow-up duration. Of the 22,236 subjects, 4,455 were included in the case group. Arthrosis, rheumatoid arthritis, neuropathies, myocardial infarction, renal disease, cancer, liver disease, and tooth extraction were associated with a higher incidence of BRONJ than subjects without such conditions (aOR, 95% CI: 1.58 [1.47-1.71], 1.46 [1.30-1.63], 1.31 [1.20-1.42], 1.23 [1.01-1.49], 1.36 [1.10-1.68], 1.27 [1.12-1.45], 1.63 [1.10-2.43], and 1.64 [1.53-1.76] respectively). In conclusion, of the factors examined, we confirmed that liver disease and tooth extraction were related to an increased risk of BRONJ.
Keywords : Bisphosphonate, Bisphosphonate-associated Osteonecrosis of the Jaw, National Insurance Database
Introduction

Bisphosphonates have been used for the management of bone metabolic diseases such as osteoporosis, Paget’s disease, hypercalcemia of malignancy, and multiple myeloma. Aside from their therapeutic use, their adverse effects have also increased in recent years.1) Osteonecrosis of the jaw is a rare but serious adverse event associated with bisphosphonate treatment. Bisphosphonates related osteonecrosis of the jaw (BRONJ) is defined as a current or previous treatment with bisphosphonates that leads to an exposed bone or bone that can be probe through a fistula in the maxillofacial region that does not heal within eight weeks.2)

BRONJ was first reported in 2002, but the underlying pathophysiology has not been fully elucidated. The prevalence of BRONJ in patients with osteoporosis ranges from 0.001 to 0.2%, whereas that in patients with cancer ranges from 0.7 to 6.7%.3-5) According to the recent study from 2012 to 2014, the cumulative incidence rates of BRONJ were 20.9 per 100,000 person-years in Korea.6)

The leading proposed hypotheses to explain the unique localization of BRONJ to the jaws include over-suppression of bone turnover or remodeling, inhibition of blood supply, constant micro-trauma, and infection/inflammation. However, none of these hypotheses seems to explain all cases.7) Besides these main factors, numerous cofactors may contribute to BRONJ pathogenesis, such as diabetes, smoking, dental extraction, concurrent medications, and others. There is a possibility that comorbidities and concurrent medications could interact with bisphosphonates, affecting remodeling, angiogenesis, and blood flow.8-10)

Risk factors reported to be related to BRONJ have been mostly done in cancer patients, as bisphosphonate is widely used to decrease the risk of skeletal-related events in patients with cancer and metastatic bone disease.11-13) However, it is important to investigate the risk factors of BRONJ in healthy community living populations due to the growing elderly population. Therefore, we aimed to examine factors associated with BRONJ development using the Senior Cohort in National Health Insurance Claims Database.

Methods

Study design and data source

In this retrospective cohort study, we used population-based representative claims data in Korea. This database contains individual beneficiary and healthcare service information including diagnosis, procedures, and prescriptions. The 10th revision of the International Classification of Diseases (ICD-10) has been used to code diagnoses. Data on elderly subjects were drawn from randomly stratified insurance claims samples. The size of the cohort was calculated and extracted to improve the representativeness of the socio-demographic characteristics, diagnosis, and healthcare services, such as prescription drugs. All data were deidentified for research purposes to protect the patients’ private information. Medical claims data are encrypted to protect personal information and are provided with anonymous identification numbers. This study was approved by the Institutional Review Board of Chungbuk National University (CBNU-201703-ETC-425).

Defining case and control groups

The first prescription date of bisphosphonate per oral or injection was set as the cohort entry date and 365 days before entry date was applied as a wash out period. Among the bisphosphonate users, subjects with missing demographic data, prescription data prior to bisphosphonate use or prescription data within 30 days before BRONJ development were excluded. Patients with one or more diagnosis of BRONJ were selected as the case group and patients without the diagnosis of BRONJ were defined as the control group. To consider the time of BRONJ development after bisphosphonate initiation, we set minimum of 30 days prior to the BRONJ diagnosis (index date). Subjects with missing data were not included in this study. Risk set sampling was used to match each case with 4 controls by age, sex, cohort entry date (±60 days) and duration of follow-up based on a nested case-control study.

Statistical analysis

Baseline characteristics were summarized for the case (BRONJ) and control groups. Results were presented as numbers and percentages for categorical variables, and differences between groups were estimated according to chi-square tests. Comorbidities including Charlson comorbidities4,14,15) and medications16) reported to be related to BRONJ were included in the analyses (Supplementary Table 1 and 2). Covariates with statistical significance in univariate analysis were entered into the multivariable analysis to estimate adjusted odds ratios. We conducted conditional logistic regression to determine significant differences between groups. All statistical analyses were done using the SAS Enterprise Guide version 9.4 (SAS Institute Inc, Cary, NC, USA), and a two-tailed confidence interval of 0.05 was considered to indicate statistical significance.

Results

Of 180,253 patients prescribed bisphosphonates, 63,253 patients met the inclusion criteria and were included in the analyses. Among them, 4,458 patients were diagnosed with BRONJ. After 1:4 matching, the case and control groups were selected, 4,455 in a case group and 17,781 in a control group (Fig. 1). The majority of patients were female (87%) and the highest number of patients were 75-79 years old in both groups (28.8% in control group and 28.9% in case group). Most of patients were prescribed oral bisphosphonates (n=21,287, 94.4%). Comorbidities included in this analysis have all shown to be statistically significant factors of BRONJ except cancers (p=0.84 in breast cancer and p=0.11 in prostate cancer). Among the Charlson comorbidity index factors, hemiplegia/paraplegia and AIDS were not statistically significantly associated with BRONJ. Antiplatelets were included as comedication in the analysis and were significantly associated with BRONJ (Table 1).

Baseline characteristics of the study subjects

Control group n=17,781 (%) BRONJ group n=4,455 (%) P value
Sex 0.810
Male 2283 (12.84) 578 (12.97)
Female 15498 (87.16) 3877 (87.03)
Age group, years 0.992
60-75 3669 (20.63) 914 (20.52)
75-79 5125 (28.82) 1286 (28.87)
80-84 4926 (27.70) 1229 (27.59)
≥85 4061 (22.84) 1026 (23.03)
Income level <0.0001
Q0-Q2 4776 (26.86) 1381 (31)
Q3-Q4 1709 (9.61) 366 (8.22)
Q5-Q6 2062 (11.6) 470 (10.55)
Q7-Q8 3913 (16.38) 683 (15.33)
Q9-Q10 6321 (35.55) 1555 (34.9)
Route of administration
Bisphosphonates oral 16985 (95.52) 4302 (96.57) 0.002
Bisphosphonates injections 935 (5.26) 334 (7.5) <0.0001
Comorbidities
Breast Cancer 68 (0.38) 18 (0.4) 0.835
Prostate Cancer 123 (0.69) 41 (0.92) 0.111
Hypertension 11470 (64.51) 3092 (69.41) <0.0001
Hyperlipidemia 6584 (37.03) 1872 (42.02) <0.0001
Arthrosis 10188 (57.3) 3126 (70.17) <0.0001
Rheumatoid arthritis 1479 (8.32) 631 (14.16) <0.0001
Neuropathies 3135 (17.63) 1128 (25.32) <0.0001
Anemia 2179 (12.25) 834 (18.72) <0.0001
Charlson comorbidity index <0.0001
0 3572 (20.09) 562 (12.62)
1-2 4223 (23.75) 888 (19.93)
≥3 9986 (56.16) 3005 (67.45)
Charlson comorbidites
Myocardial infarction 414 (2.33) 165 (3.7) <0.0001
Congestive heart failure 1707 (9.6) 545 (12.23) <0.0001
Peripheral vascular disease 3766 (21.18) 1187 (26.64) <0.0001
Cerebrovascular disease 3749 (21.08) 1029 (23.10) 0.003
Renal disease 312 (1.75) 148 (3.32) <0.0001
Cancer 1301 (7.32) 466 (10.46) <0.0001
Rheumatic disease 290 (1.63) 149 (3.34) <0.0001
Peptic ulcer disease 6522 (36.68) 1996 (44.8) <0.0001
Mild liver disease 3727 (20.96) 1119 (25.12) <0.0001
Diabetes without chronic complication 4503 (25.32) 1476 (33.13) <0.0001
Diabetes with chronic complication 2098 (11.8) 725 (16.27) <0.0001
Liver disease 77 (0.43) 41 (0.92) <0.0001
Hemiplegia or paraplegia 455 (2.56) 137 (3.08) 0.056
Metastatic solid tumor 156 (0.88) 61 (1.37) 0.003
AIDS 3 (0.02) 1 (0.02) 0.804
Tooth extraction 9018 (50.72) 2775 (62.29) <0.0001
Co-medication
Antiplatelet 6754 (37.98) 1954 (43.86) <0.0001



Fig. 1. A flowchart showing patient selection

After adjusting for statistically significant factors from univariate analysis, arthrosis, tooth extraction, bisphosphonate use, and liver disease were more pronounced factors associated with greater BRONJ development (aOR>1.5). Other statistically significant factors including rheumatoid arthritis, neuropathies, anemia, antiplatelet use, myocardial infarction, renal disease, cancer, peptic ulcer disease, and diabetes without chronic complication have shown slight association with greater BRONJ development (aOR of 1.0-1.5) (Table 2).

Factors associated with BRONJ using multivariable logistic regression analysis

Variable Crude odds ratio (95% CI) Adjusted odds ratio (95% CI)
Comorbidities
Breast Cancer 1.05 (0.63–1.78) 0.78 (0.45-1.35)
Prostate Cancer 1.32 (0.96-1.92) 0.82 (0.55-1.23)
Hypertension 1.25 (1.16-1.34) 1.04 (0.96-1.13)
Hyperlipemia 1.24 (1.16-1.33) 0.96 (0.89-1.04)
Arthrosis 1.77 (1.65-1.90) 1.58 (1.47-1.71)
Rheumatoid arthritis 1.83 (1.65-2.02) 1.46 (1.30-1.63)
Neuropathies 1.58 (1.46-1.71) 1.31 (1.20-1.42)
Anemia 1.65 (1.51-1.81) 1.32 (1.20-1.45)
Co-medication
Antiplatelet 1.27 (1.1951.36) 1.09 (1.01-1.18)
Route of administration
Bisphosphonates oral 1.32 (1.10-1.58) 1.55 (1.28-1.88)
Bisphosphonates injections 1.47 (1.28-1.67) 1.52 (1.32-1.76)
Tooth extraction 1.65 (1.54-1.77) 1.64 (1.53-1.76)
Charlson comorbidites
Myocardial infarction 1.60 (1.33-1.93) 1.23 (1.01-1.49)
Congestive heart failure 1.31 (1.18-1.45) 1.04 (0.93-1.16)
Peripheral vascular disease 1.35 (1.25-1.46) 1.09 (1.00-1.18
Cerebrovascular disease 1.12 (1.04-1.21) 0.88 (0.80-0.97)
Renal disease 1.91 (1.57-2.34) 1.36 (1.10-1.68)
Cancer 1.49 (1.33-1.67) 1.27 (1.12-1.45)
Rheumatic disease 2.07 (1.70-2.53) 1.24 (0.99-1.55)
Peptic ulcer disease 1.40 (1.31-1.50) 1.09 (1.01-1.17)
Mild liver disease 1.26 (1.17-1.36) 0.95 (0.87-1.04)
Diabetes without chronic complication 1.46 (1.36-1.57) 1.18 (1.08-1.28)
Diabetes with chronic complication 1.45 (1.32-1.59) 1.06 (0.95-1.18)
Hemiplegia or paraplegia 1.2 (0.99-1.46) 1.04 (0.85-1.28)
Liver disease 2.14 (1.46-3.17) 1.63 (1.10-2.43)
Metastatic solid tumor 1.57 (1.16-2.21) 1.09 (0.78-1.52)
AIDS 1.33 (0.13-12.81) 1.15 (0.11-11.76)

Discussion

The main finding of this study is that unreported factor such as liver disease was associated with increased risk of BRONJ as well as the known factor including tooth extraction.

Previous studies on risk factors of BRONJ reported various factors including tooth extractions, advanced age, anemia, diabetes, and cancer.4,14,15) However, these previous studies had limited number of patients and these factors were controversial because of the rarity of BRONJ. A nationwide cohort study in Taiwan showed that the prevalence of BRONJ was higher in patients with history of tooth extraction and intravenous route of administration.17) In patients treated with intravenous bisphosphonates, the prevalence of BRONJ reportedly ranges from <1% to 28%. Typically, in these studies, the lower estimates included data from patients with osteoporosis and the higher figures were obtained from patients with cancer, without control cohorts. In the present study, bisphosphonate therapy itself, regardless of the delivery route, was confirmed to be a significant risk factor for BRONJ (adjusted OR=1.55 in oral and 1.52 in intravenous route).

It has been established that BRONJ are associated with tooth extractions in previous studies.14,18) Similarly, we noted a significant difference in the distribution of BRONJ between those who had undergone tooth extraction and those who had not among the study population (adjusted odds ratio=1.64, 95% CI=1.53-1.76).

Moreover, liver disease has also shown statistical significance for BRONJ development. It is known that bisphosphonates doses are independent of hepatic impairment. Also, there are no association reported between bisphosphonates and liver disease. The pharmacokinetics nor the pharmacodynamics characteristics of bisphosphonates does not seemed to be linked to osteonecrosis at this point. Thus, present study results were unexpected and needs further investigation.

One of the limitations of this study is that possible social factors such as smoking was not included due to the lack of data availability. Also, various concurrent medications were not taken account because previous studies on associated medication with BRONJ were limited. Further research is needed to investigate the effects of other medications and subgroup analysis on a specific disease group will provide more information.

Conclusion

Risk factors such as arthrosis, tooth extraction, and liver disease may play a significant role in patients initiating bisphosphonate treatment which warrants close monitoring or changes in pharmacotherapy.

Supplemental Materials
yakhak-66-4-210-Supple.pdf
Acknowledgment

This study was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education (2020R1F1A1069718).

Conflict of Interest

The authors declare that they have no conflict of interest.

References
  1. Ruggiero SL (2011) Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 1218: 38-46.
    Pubmed CrossRef
  2. Gupta M, Gupta N (2022) Bisphosphonate Related Jaw Osteonecrosis. StatPearls. Treasure Island (FL): StatPearls Publishing.
  3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72: 1938-1956.
    Pubmed CrossRef
  4. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. J Bone Miner Res 30: 3-23.
    Pubmed CrossRef
  5. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J (2017) Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom 20: 8-24.
    Pubmed CrossRef
  6. Kim SH, Lee YK, Kim TY, Ha YC, Jang S, Kim HY (2021) Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study. Bone 143: 115650.
    Pubmed CrossRef
  7. Allen MR, Burr DB (2009) The pathogenesis of bisphosphonaterelated osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67: 61-70.
    Pubmed CrossRef
  8. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, Elad S (2007) Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92: 1172-1175.
    Pubmed CrossRef
  9. Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66: 625-631.
    Pubmed KoreaMed CrossRef
  10. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65: 369-376.
    Pubmed CrossRef
  11. Matsuo A, Hamada H, Takahashi H, Okamoto A, Kaise H, Chikazu D (2016) Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients. Odontology 104: 363-371.
    Pubmed CrossRef
  12. Utreja A, Almas K, Javed F (2013) Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update. Odontostomatol Trop 36: 38-46.
  13. Assaf AT, Smeets R, Riecke B, Weise E, Gröbe A, Blessmann M, Steiner T, Wikner J, Friedrich RE, Heiland M, Hoelzle F, Gerhards F (2013) Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res 33: 3917-3924.
  14. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE (2011) Risk Factors for Osteonecrosis of the Jaws: a Case-Control Study from the CONDOR Dental PBRN. J Dent Res 90: 439-444.
    Pubmed KoreaMed CrossRef
  15. Yamazaki T, Yamori M, Yamamoto K, Saito K, Asai K, Sumi E, Goto K, Takahashi K, Nakayama T, Bessho K (2012) Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. Bone 51: 882-887.
    Pubmed CrossRef
  16. Giudice A, Esposito M, Bennardo F, Brancaccio Y, Buti J, Fortunato L (2019) Dental extractions for patients on oral antiplatelet: a within-person randomised controlled trial comparing haemostatic plugs, advanced-platelet-rich fibrin (A-PRF+) plugs, leukocyte- and platelet-rich fibrin (L-PRF) plugs and suturing alone. Int J Oral Implantol (Berl) 12: 77-87.
  17. Yuh DY, Chang TH, Huang RY, Chien WC, Lin FG, Fu E (2014) The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan. J Dent 42: 1343-1352.
    Pubmed CrossRef
  18. Almazrooa SA, Woo SB (2009) Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 140: 864-875.
    Pubmed CrossRef


August 2022, 66 (4)
Full Text(PDF) Free
Supplementary File

Social Network Service
Services

Cited By Articles
  • CrossRef (0)